The 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) will be held from April 29 to May 2, 2019 in Washington, DC, USA.
Julianne Smith, Ph.D., Vice President of Translational Sciences at Cellectis, will be participating in a corporate review session at the Gene Editing Workshop on Sunday, April 28, 2019 from 5:00 PM to 6:00 PM EDT. Julianne will also be giving a presentation entitled “Allogeneic Gene-Edited CAR T-Cells: From Preclinical to Clinical Proof of Concept” on Tuesday, April 30 from 8:00 AM to 8:30 AM EDT during the Scientific Symposium “Towards the Holy Grail of Cancer Gene Therapies: Universal Cells, Targeted Vectors and Solid Tumor CART Efficacy”.
Philippe Duchateau, Ph.D., Chief Scientific Officer at Cellectis, will be participating in the Scientific Symposium with a presentation titled, "Universal Gene-Edited CAR T-Cell Immunotherapy" on Monday, April 29 from 8:00 - 10:00 AM EDT.
Roman Galetto, Ph.D., Preclinical Manager at Cellectis, will be giving the oral presentation on "UCARTCS1A: Allogeneic CAR T-Cells Targeting CS1 as Treatment for Multiple Myeloma" in the CAR-T Cell Therapies for Cancer session on Monday, April 29 from 3:45 PM - 4:00 PM EDT.
Ming Yang, Ph.D., Project Leader at Cellectis, will be giving a poster presentation on "A Straightforward and Efficient Strategy to Generate Universal CAR T-Cells" in the Cell Therapies III Session on Wednesday, May 1 from 5:00 PM - 6:00 PM EDT.
April 28, 2019
‐ May 02, 2019
Washington, DC, USA